Last updated 16 days ago
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
500 patients around the world
Available in Colombia, Chile, Argentina, United States, Mexico, Belgium, Spain
Bristol-Myers Squibb
4Research sites
500Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Non-squamous NSCLC, not amenable to treatment in curative intent.Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).
- Inadequate organ function and/or bone marrow reserve.Leptomeningeal metastases or spinal cord compression.Poorly controlled systemic medical conditions.Other protocol-defined inclusion/exclusion criteria apply.
Sites
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Hospital Privado de Córdoba
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Recruiting
StudyIZABRIGHT-Lung01
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07100080
